Insider trust linked to IRADIMED (NASDAQ: IRMD) sells 7,500 shares

Rhea-AI Filing Summary

IRADIMED CORP director and CEO Roger E. Susi reported indirect open-market sales of company common stock through the Phillip Susi 2008 Dynasty Trust. On March 16–17, 2026, the trust sold a total of 7,500 shares at weighted average prices of about $101.18, $101.68 and $102.43 per share.

The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025, indicating they were scheduled in advance. After these transactions, the Phillip Susi 2008 Dynasty Trust holds 2,240,000 shares. The filing also lists additional indirect holdings of 162,950 shares via the Roger E. Susi Revocable Trust and 2,062,500 shares via the Matthew Susi 2008 Dynasty Trust, with Susi disclaiming beneficial ownership beyond his pecuniary interest.

Insights

Equity analyst – insider activity

Pre-planned, small insider sales with large indirect stake remaining.

The filing shows open-market sales of 7,500 IRADIMED CORP shares by the Phillip Susi 2008 Dynasty Trust at prices around $101–$102. These were executed under a Rule 10b5-1 plan, which is typically established in advance to automate trading.

After these transactions, the trust still holds 2,240,000 shares, and other trusts collectively hold hundreds of thousands more. Relative to these indirect positions, the sale size appears small, suggesting a routine liquidity or diversification pattern rather than a major change in exposure. Susi also formally disclaims beneficial ownership beyond his pecuniary interest, emphasizing that the shares are held in trust structures.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Susi Roger E.

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FLORIDA 32826

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, PRESIDENT, CHAIRMAN

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		S(1)		3,009	D	$101.18(2)	2,244,491	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	03/16/2026		S(1)		1,991	D	$101.68(3)	2,242,500	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	03/17/2026		S(1)		2,500	D	$102.43(4)	2,240,000	I	By Phillip Susi 2008 Dynasty Trust
Common Stock								162,950	I	By Roger E. Susi Revocable Trust
Common Stock								2,062,500(5)	I	By Matthew Susi 2008 Dynasty Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.

2. This transaction was executed in multiple trades at prices ranging from $100.37 to $101.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $101.38 to $101.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $102.06 to $102.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Roger E. Susi	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did IRADIMED (IRMD) report in this Form 4?

IRADIMED reported that a trust linked to CEO Roger E. Susi sold 7,500 shares of common stock. The Phillip Susi 2008 Dynasty Trust executed open-market sales on March 16–17, 2026 at prices around $101–$102 per share under a pre-arranged Rule 10b5-1 plan.

At what prices were the IRADIMED (IRMD) shares sold in this filing?

The disclosed sales occurred at weighted average prices near $101–$102 per share. Individual transactions were reported at approximately $101.18, $101.68 and $102.43, with trades executed in multiple lots within stated intraday price ranges for each transaction date.

How many IRADIMED (IRMD) shares does the selling trust hold after these transactions?

After the reported sales, the Phillip Susi 2008 Dynasty Trust holds 2,240,000 IRADIMED shares. This remaining position indicates that the 7,500 shares sold represent a small portion of the trust’s overall indirect ownership stake in the company.

Were the IRADIMED (IRMD) insider sales pre-planned under a Rule 10b5-1 plan?

Yes, the filing states the sales were made under a Rule 10b5-1 trading plan. The plan was adopted on November 5, 2025, indicating the March 2026 transactions were scheduled in advance rather than timed discretionarily around short-term market events.

What other indirect IRADIMED (IRMD) holdings are reported for Roger E. Susi?

The Form 4 lists additional indirect holdings through other trusts. These include 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust, with Susi disclaiming beneficial ownership beyond any pecuniary interest.

Does Roger E. Susi claim full beneficial ownership of the IRADIMED (IRMD) trust shares?

No, the filing includes a disclaimer of full beneficial ownership. It states that Susi disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest, clarifying the legal treatment of shares held through the referenced trust structures.